Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(2): 124-131


Mass Spectrometry investigation of 17α-Ethinylestradiol and Drospirenone complete removal from synthetic wastewater using Ozonation

Phellipe H. Amaral, Daniel M. Oliveira, Alexandre Romanini, Elias P. Tessaro, Jose E. Padilha, Deleon N. Correa, Nelci F. Hoehr, Marcos N. Eberlin, Giovana A Bataglion, Eduardo C. Meurer.




Abstract

17α-ethinylestradiol (EE2) and drospirenone (DRO) are steroidal birth control compounds of widespread use and the presence of these two compounds in effluents and drink water have been related with a variety of diseases such as cancer and metabolic changes in humans. This paper describes the use of FT-ICR-MS and HPLC-MS/MS to investigate the removal of EE2 and DRO from synthetic wastewater simulating an industrial pilot plant residue, using an ozone treatment pilot plant. Ab initio calculations have been also performed suggesting that the lower energy pathway for drug degradation involves the action of singlet oxygen to these steroidal species. Total elimination of EE2 and DRO were achieved after 3 and 28 min, respectively. Estrogens degradations were screened via FT-ICR MS analyses in both positive and negative ion modes, and no residual organic molecules could be detected showing extensive oxidation and near total conversion to small volatiles or inorganic material.

Key words: Mass Spectrometry, 17α-ethinylestradiol, Drosperinone, Ozonation.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.